International trade · 10/12/2025Updated: 10/17/2026 · 1 min read
U.S. Patent Office Extends Patent Term for Bitopertin Oral Tablets
Summary
The United States Patent and Trademark Office has granted a one-year extension to the term of U.S. Patent No. 7,319,099, allowing the patent holder to continue protecting their Bitopertin (GlyT1 inhibitor) Oral Tablets for an additional year.
Original source language: Federal Register — Department of CommerceOpen original release →